$EVMN SEC Filings

Filed On	Filing
15 Oct 2026	Form 4: Pena Luis C., Director Received 1,115 shares as a grant or award ($7.83K)
01 Oct 2026	8-K: Regulation FD Disclosure Evommune Presents Late-Breaking Phase 2a Proof-of-Concept Data Evaluating EVO301 in Atopic Dermatitis at European Academy of Dermatology and Venereology Congress
23 Sep 2026	8-K: Regulation FD Disclosure Evommune Announces Late-Breaker Presentation of Phase 2a Data for EVO301 in Atopic Dermatitis at European Academy of Dermatology & Venereology 2026 Congress
15 Sep 2026	8-K: Regulation FD Disclosure Evommune Corporate Presentation September 2026 © Evommune, Inc.
09 Sep 2026	424B3
09 Sep 2026	8-K: Regulation FD Disclosure; Other Events ‑ Trial did not meet the primary endpoint of percent change in Eczema Area and Severity Index (EASI) score from baseline at Week 12; EVO756 was generally well tolerated
14 Aug 2026	SCHEDULE 13G/A
14 Aug 2026	SCHEDULE 13G
06 Aug 2026	424B3
06 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition
30 Jul 2026	8-K: Regulation FD Disclosure
16 Jul 2026	SCHEDULE 13G
10 Jul 2026	Form 4: Carver Kyle, Chief Financial Officer Bought 1,000 shares ($13.3K)
08 Jul 2026	Form 4: Kirsch Arthur S, Director Bought 10,000 shares ($133K)
29 Jun 2026	424B3
29 Jun 2026	8-K: Regulation FD Disclosure; Other Events
24 Jun 2026	Form 4: Drew Janice Suzann, Chief of Dev. Operations Received 20,000 shares by exercise or conversion ($63.1K) · Sold 20,000 shares ($453K)
24 Jun 2026	Form 4: Patel Jeegar Pravinkumar, Chief Scientific Officer Received 1,488 shares by exercise or conversion ($5.71K) · Sold 1,488 shares ($33.5K)
24 Jun 2026	Form 4: Pena Luis C., Director Sold 7,438 shares ($169K)

Comments